Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2009, Article ID 706852, 12 pages
http://dx.doi.org/10.1155/2009/706852
Research Article

MBX-102/JNJ39659100, a Novel Non-TZD Selective Partial PPAR- 𝛾 Agonist Lowers Triglyceride Independently of PPAR- 𝛼 Activation

1Department of Biology, Metabolex, Inc., 3876 Bay Center Place, Hayward, CA 94545, USA
2Department of Molecular Biology, Genentech Inc., 1 DNA Way, South San Francisco, CA 94080, USA

Received 3 December 2008; Accepted 7 February 2009

Academic Editor: Anna Tsantili-Kakoulidou

Copyright © 2009 Apurva Chandalia et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. N. Feige, L. Gelman, L. Michalik, B. Desvergne, and W. Wahli, “From molecular action to physiological outputs: peroxisome proliferator-activated receptors are nuclear receptors at the crossroads of key cellular functions,” Progress in Lipid Research, vol. 45, no. 2, pp. 120–159, 2006. View at Publisher · View at Google Scholar · View at PubMed
  2. L. Michalik, J. Auwerx, J. P. Berger et al., “International Union of Pharmacology. LXI. Peroxisome proliferator-activated receptors,” Pharmacological Reviews, vol. 58, no. 4, pp. 726–741, 2006. View at Publisher · View at Google Scholar · View at PubMed
  3. S. Kersten, “Peroxisome proliferator activated receptors and lipoprotein metabolism,” PPAR Research, vol. 2008, Article ID 132960, 11 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  4. B. Staels, J. Dallongeville, J. Auwerx, K. Schoonjans, E. Leitersdorf, and J.-C. Fruchart, “Mechanism of action of fibrates on lipid and lipoprotein metabolism,” Circulation, vol. 98, no. 19, pp. 2088–2093, 1998. View at Google Scholar
  5. D. L. Sprecher, “Lipids, lipoproteins, and peroxisome proliferator activated receptor-δ,” The American Journal of Cardiology, vol. 100, no. 11, supplement 1, pp. S20–S24, 2007. View at Publisher · View at Google Scholar · View at PubMed
  6. D. L. Sprecher, C. Massien, G. Pearce et al., “Triglyceride: high-density lipoprotein cholesterol effects in healthy subjects administered a peroxisome proliferator activated receptor δ agonist,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 2, pp. 359–365, 2007. View at Publisher · View at Google Scholar · View at PubMed
  7. S. M. Reilly and C.-H. Lee, “PPARδ as a therapeutic target in metabolic disease,” FEBS Letters, vol. 582, no. 1, pp. 26–31, 2008. View at Publisher · View at Google Scholar · View at PubMed
  8. J. A. Madrazo and D. P. Kelly, “The PPAR trio: regulators of myocardial energy metabolism in health and disease,” Journal of Molecular and Cellular Cardiology, vol. 44, no. 6, pp. 968–975, 2008. View at Publisher · View at Google Scholar · View at PubMed
  9. M. Schmuth, Y. J. Jiang, P. M. Elias, and K. R. Feingold, “Thematic review series: skin lipids. Peroxisome proliferator-activated receptors and liver X receptors in epidermal biology,” Journal of Lipid Research, vol. 49, no. 3, pp. 499–509, 2008. View at Publisher · View at Google Scholar · View at PubMed
  10. A. Iwashita, Y. Muramatsu, T. Yamazaki et al., “Neuroprotective efficacy of the peroxisome proliferator-activated receptor δ-selective agonists in vitro and in vivo,” Journal of Pharmacology and Experimental Therapeutics, vol. 320, no. 3, pp. 1087–1096, 2007. View at Publisher · View at Google Scholar · View at PubMed
  11. J. M. Peters, H. E. Hollingshead, and F. J. Gonzalez, “Role of peroxisome-proliferator-activated receptor β/δ (PPARβ/δ) in gastrointestinal tract function and disease,” Clinical Science, vol. 115, no. 3-4, pp. 107–127, 2008. View at Publisher · View at Google Scholar · View at PubMed
  12. T. M. Willson, J. E. Cobb, D. J. Cowan et al., “The structure-activity relationship between peroxisome proliferator-activated receptor γ agonism and the antihyperglycemic activity of thiazolidinediones,” Journal of Medicinal Chemistry, vol. 39, no. 3, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at PubMed
  13. M. A. Deeg and M. H. Tan, “Pioglitazone versus rosiglitazone: effects on lipids, lipoproteins, and apolipoproteins in head-to-head randomized clinical studies,” PPAR Research, vol. 2008, Article ID 520465, 6 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  14. S. Bavirti, F. Ghanaat, and J. A. Tayek, “Peroxisome proliferator-activated receptor-gamma agonist increases both low-density lipoprotein cholesterol particle size and small high-density lipoprotein cholesterol in patients with type 2 diabetes independent of diabetic control,” Endocrine Practice, vol. 9, no. 6, pp. 487–493, 2003. View at Google Scholar
  15. A. Rubenstrunk, R. Hanf, D. W. Hum, J.-C. Fruchart, and B. Staels, “Safety issues and prospects for future generations of PPAR modulators,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1065–1081, 2007. View at Publisher · View at Google Scholar · View at PubMed
  16. T. Yang and S. Soodvilai, “Renal and vascular mechanisms of thiazolidinedione-induced fluid retention,” PPAR Research, vol. 2008, Article ID 943614, 8 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  17. B. G. Shearer and A. N. Billin, “The next generation of PPAR drugs: do we have the tools to find them?,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1082–1093, 2007. View at Publisher · View at Google Scholar · View at PubMed
  18. A. Grey, “Skeletal consequences of thiazolidinedione therapy,” Osteoporosis International, vol. 19, no. 2, pp. 129–137, 2008. View at Publisher · View at Google Scholar · View at PubMed
  19. V. Fonseca, “Effect of thiazolidinediones on body weight in patients with diabetes mellitus,” The American Journal of Medicine, vol. 115, no. 8, supplement 1, pp. 42–48, 2003. View at Publisher · View at Google Scholar
  20. F. Zhang, B. E. Lavan, and F. M. Gregoire, “Selective modulators of PPAR-γ activity: molecular aspects related to obesity and side-effects,” PPAR Research, vol. 2007, Article ID 32696, 7 pages, 2007. View at Publisher · View at Google Scholar · View at PubMed
  21. R. W. Nesto, D. Bell, R. O. Bonow et al., “Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association,” Diabetes Care, vol. 27, no. 1, pp. 256–263, 2004. View at Publisher · View at Google Scholar
  22. A. M. Lincoff, K. Wolski, S. J. Nicholls, and S. E. Nissen, “Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials,” The Journal of the American Medical Association, vol. 298, no. 10, pp. 1180–1188, 2007. View at Publisher · View at Google Scholar · View at PubMed
  23. S. E. Nissen and K. Wolski, “Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes,” The New England Journal of Medicine, vol. 356, no. 24, pp. 2457–2471, 2007. View at Publisher · View at Google Scholar · View at PubMed
  24. O. P. Lazarenko, S. O. Rzonca, W. R. Hogue, F. L. Swain, L. J. Suva, and B. Lecka-Czernik, “Rosiglitazone induces decreases in bone mass and strength that are reminiscent of aged bone,” Endocrinology, vol. 148, no. 6, pp. 2669–2680, 2007. View at Publisher · View at Google Scholar · View at PubMed
  25. S. O. Rzonca, L. J. Suva, D. Gaddy, D. C. Montague, and B. Lecka-Czernik, “Bone is a target for the antidiabetic compound rosiglitazone,” Endocrinology, vol. 145, no. 1, pp. 401–406, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. V. Sottile, K. Seuwen, and M. Kneissel, “Enhanced marrow adipogenesis and bone resorption in estrogen-deprived rats treated with the PPARgamma agonist BRL49653 (rosiglitazone),” Calcified Tissue International, vol. 75, no. 4, pp. 329–337, 2004. View at Publisher · View at Google Scholar · View at PubMed
  27. C. Meier, M. E. Kraenzlin, M. Bodmer, S. S. Jick, H. Jick, and C. R. Meier, “Use of thiazolidinediones and fracture risk,” Archives of Internal Medicine, vol. 168, no. 8, pp. 820–825, 2008. View at Publisher · View at Google Scholar · View at PubMed
  28. A. V. Schwartz, “TZDs and bone: a review of the recent clinical evidence,” PPAR Research, vol. 2008, Article ID 297893, 6 pages, 2008. View at Publisher · View at Google Scholar · View at PubMed
  29. B. L. Balint and L. Nagy, “Selective modulators of PPAR activity as new therapeutic tools in metabolic diseases,” Endocrine, Metabolic and Immune Disorders Drug Targets, vol. 6, no. 1, pp. 33–43, 2006. View at Google Scholar
  30. M. C. Carmona, K. Louche, B. Lefebvre et al., “S 26948: a new specific peroxisome proliferator-activated receptor γ modulator with potent antidiabetes and antiatherogenic effects,” Diabetes, vol. 56, no. 11, pp. 2797–2808, 2007. View at Publisher · View at Google Scholar · View at PubMed
  31. M. Einstein, T. E. Akiyama, G. A. Castriota et al., “The differential interactions of peroxisome proliferator-activated receptor γ ligands with Tyr473 is a physical basis for their unique biological activities,” Molecular Pharmacology, vol. 73, no. 1, pp. 62–74, 2008. View at Publisher · View at Google Scholar · View at PubMed
  32. L. Gelman, J. N. Feige, and B. Desvergne, “Molecular basis of selective PPARγ modulation for the treatment of type 2 diabetes,” Biochimica et Biophysica Acta, vol. 1771, no. 8, pp. 1094–1107, 2007. View at Publisher · View at Google Scholar · View at PubMed
  33. F. Chang, L. A. Jaber, H. D. Berlie, and M. B. O'Connell, “Evolution of peroxisome proliferator-activated receptor agonists,” Annals of Pharmacotherapy, vol. 41, no. 6, pp. 973–983, 2007. View at Publisher · View at Google Scholar · View at PubMed
  34. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, and N. P. Papageorge's, “Effect of halofenate on serum uric acid,” Clinical Pharmacology and Therapeutics, vol. 14, no. 3, pp. 371–373, 1973. View at Google Scholar
  35. W. S. Aronow, P. R. Harding, M. Khursheed, J. S. Vangrow, N. P. Papageorge's, and J. Mays, “Effect of halofenate on serum lipids,” Clinical Pharmacology and Therapeutics, vol. 14, no. 3, pp. 358–365, 1973. View at Google Scholar
  36. E. B. Feldman, F. B. Gluck, and A. C. Carter, “Effects of halofenate on glucose tolerance in patients with hyperlipoproteinemia,” Journal of Clinical Pharmacology, vol. 18, no. 5-6, pp. 241–248, 1978. View at Google Scholar
  37. L. H. Krut, H. C. Seftel, and B. I. Joffe, “Comparison of clofibrate with halofenate in diabetics with hyperlipidaemia,” South African Medical Journal, vol. 51, no. 11, pp. 348–352, 1977. View at Google Scholar
  38. T. Allen, F. Zhang, S. A. Moodie et al., “Halofenate is a selective peroxisome proliferator-activated receptorγ modulator with antidiabetic activity,” Diabetes, vol. 55, no. 9, pp. 2523–2533, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. P. Trinder, “Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen,” Journal of Clinical Pathology, vol. 22, no. 2, pp. 158–161, 1969. View at Publisher · View at Google Scholar
  40. M. Stumvoll, B. J. Goldstein, and T. W. van Haeften, “Type 2 diabetes: principles of pathogenesis and therapy,” The Lancet, vol. 365, no. 9467, pp. 1333–1346, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. I. W. Campbell, “The clinical significance of PPAR gamma agonism,” Current Molecular Medicine, vol. 5, no. 3, pp. 349–363, 2005. View at Publisher · View at Google Scholar
  42. J. Waugh, G. M. Keating, G. L. Plosker, S. Easthope, and D. M. Robinson, “Pioglitazone: a review of its use in type 2 diabetes mellitus,” Drugs, vol. 66, no. 1, pp. 85–109, 2006. View at Publisher · View at Google Scholar
  43. J. Remick, H. Weintraub, R. Setton, J. Offenbacher, E. Fisher, and A. Schwartzbard, “Fibrate therapy: an update,” Cardiology in Review, vol. 16, no. 3, pp. 129–141, 2008. View at Publisher · View at Google Scholar · View at PubMed
  44. P. Duriez, “Mechanisms of actions of statins and fibrates,” Therapie, vol. 58, no. 1, pp. 5–14, 2003. View at Publisher · View at Google Scholar
  45. R. B. Goldberg, D. M. Kendall, M. A. Deeg et al., “A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia,” Diabetes Care, vol. 28, no. 7, pp. 1547–1554, 2005. View at Publisher · View at Google Scholar
  46. J. Rosenstock, F. Flores-Lozano, S. Schartz, G. Gonzalez-Galvez, and D. Karpf, “MBX-102: a novel non-TZD insulin sensitizer that improves glycemic control without causing edema or weight gain in patients with type 2 diabetes (T2DM) on concomitant insulin therapy,” Diabetes, vol. 54, 2005, abstract no. 44-OR. View at Google Scholar
  47. W. S. Aronow, M. D. Vicario, K. Moorthy, J. King, M. Vawter, and N. P. Papageorge's, “Long term efficacy of halofenate on serum triglyceride levels,” Current Therapeutic Research, Clinical and Experimental, vol. 18, no. 6, pp. 855–861, 1975. View at Google Scholar
  48. C. A. Dujovne, D. L. Azarnoff, D. H. Huffman, P. Pentikäinen, A. Hurwitz, and D. W. Shoeman, “One year trials with halofenate, clofibrate, and placebo,” Clinical Pharmacology and Therapeutics, vol. 19, no. 3, pp. 352–359, 1976. View at Google Scholar
  49. C. A. Dujovne, D. L. Azarnoff, P. Pentikainen, C. Manion, A. Hurwitz, and K. Hassanein, “A two year crossover therapeutic trial with halofenate and clofibrate,” The American Journal of the Medical Sciences, vol. 272, no. 3, pp. 277–284, 1976. View at Google Scholar
  50. D. Patsouris, J. K. Reddy, M. Müller, and S. Kersten, “Peroxisome proliferator-activated receptor α mediates the effects of high-fat diet on hepatic gene expression,” Endocrinology, vol. 147, no. 3, pp. 1508–1516, 2006. View at Publisher · View at Google Scholar · View at PubMed
  51. B. Staels, N. Vu-Dac, V. A. Kosykh et al., “Fibrates downregulate apolipoprotein C-III expression independent of induction of peroxisomal acyl coenzyme A oxidase. A potential mechanism for the hypolipidemic action of fibrates,” The Journal of Clinical Investigation, vol. 95, no. 2, pp. 705–712, 1995. View at Publisher · View at Google Scholar · View at PubMed
  52. J. Sakamoto, H. Kimura, S. Moriyama et al., “Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone,” Biochemical and Biophysical Research Communications, vol. 278, no. 3, pp. 704–711, 2000. View at Publisher · View at Google Scholar · View at PubMed
  53. S. Qin, T. Liu, V. S. Kamanna, and M. L. Kashyap, “Pioglitazone stimulates apolipoprotein A-I production without affecting HDL removal in HepG2 cells: involvement of PPAR-α,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 11, pp. 2428–2434, 2007. View at Publisher · View at Google Scholar · View at PubMed
  54. R. J. Cenedella and W. G. Crouthamel, “Halofenate and clofibrate: mechanism of hypotriglyceridemic action in the rat,” Journal of Lipid Research, vol. 17, no. 2, pp. 156–166, 1976. View at Google Scholar